Vista Pharmaceuticals (524711) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
13 Aug, 2025Executive summary
Board approved unaudited financial results for the quarter ended June 30, 2025, and scheduled the 34th AGM for September 30, 2025, via video conferencing.
Re-appointments of key directors, including Managing Director and Whole Time Directors, were recommended for new three-year terms, subject to shareholder approval.
Financial highlights
Revenue from operations for Q1 FY26 was ₹151.88 lakhs, down from ₹179.50 lakhs in Q1 FY25.
Loss before tax for the quarter was ₹148.01 lakhs, compared to a profit before tax of ₹117.13 lakhs in the same quarter last year.
Net loss for the quarter stood at ₹129.04 lakhs, versus a net loss of ₹85.70 lakhs year-over-year.
Basic and diluted EPS for the quarter were both -₹0.22, compared to -₹0.15 in the prior year quarter.
Outlook and guidance
Board approved convening the AGM and re-appointments, indicating continuity in leadership and governance.
Latest events from Vista Pharmaceuticals
- Nil revenue, continued losses, and NPA status raise significant going concern risks.524711
Q1 26/27 - Audited FY26 results received an unqualified opinion; new internal auditor appointed for FY27.524711Q4 25/26
- Q3 FY26 saw higher net loss and ECL provision, with statutory dues outstanding.524711Q3 25/26
- Q2 FY26 saw lower revenue, higher losses, and major ECL provisioning amid new capital raised.524711Q2 25/26
- Q2 FY25 saw lower revenue but reduced losses and stronger equity from capital raising.524711Q2 24/25
- Q1 FY25 saw lower revenue and a net loss, with AGM scheduled for September 30, 2024.524711Q1 24/25
- Net loss persists despite revenue growth; WHO certification and audit opinion boost credibility.524711Q4 24/25
- Q3 FY25 revenue surged, but losses continued; WHO certification marks a key milestone.524711Q3 24/25